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Abstract
Purpose The quality of life (QL) of advanced gastric
cancer patients receiving irinotecan, folinic acid and 5-
ﬂuorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF
arm) is presented.
Methods Patients with measurable or evaluable advanced
gastric cancer received IF weekly for 6/7 weeks or CF
q4 weeks. QL was assessed using the EORTC QLQ-C30 at
baseline, subsequently every 8 weeks until progression and
thereafter every 3 months until death. The QL data were
analysed using several statistical methods including sum-
mary measures and pattern-mixture modelling.
Results A total of 333 patients were randomised and
treated (IF 170, CF 163). The time-to-progression for IF
and CF was 5.0 and 4.2 months (P = 0.088), respectively.
The overall compliance rates for QL questionnaire
completion were 60 and 56% in the IF and CF arms,
respectively. Signiﬁcant treatment differences were
observed for the physical functioning scale (P = 0.024),
nausea\vomiting (P = 0.001) and EQ-5D thermometer
(P = 0.020) in favour of the IF treatment arm.
Conclusion There was a trend in favour of IF over CF in
time-to-progression. The IF group also demonstrated a
better safety proﬁle than CF and a better QL on a number
of multi-item scales, suggesting that IF offers an alternative
ﬁrst-line platinum-free treatment option for advanced gas-
tric cancer.
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Introduction
Gastric cancer is the second most common cause of cancer
mortality worldwide [1]. Patients with advanced disease
represent over two-thirds of newly diagnosed cases [2].
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DOI 10.1007/s11136-009-9493-zDespite advances in diagnosis and treatment, the prognosis
for patients with advanced disease remains poor with the
median survival reported to range from 5.3 to 10.2 months
[3]. Several randomised trials demonstrated survival and
quality of life (QL) beneﬁts of chemotherapy compared
with best supportive care [4]. Fluorouracil (5-FU) remains
one of the most widely used drugs with the introduction of
several other agents including cisplatin and anthracyclines
being investigated in doublet and triplet combinations
together with 5-FU or capcitabene [5–7]. The survival
advantage of any of these combination regimens, compared
with each other, is small and as such no internationally
accepted standard of care regimen has emerged [6, 8]. The
primary objectives of treatment in this palliative setting are
to relieve symptoms, improve QL and prolong survival [9,
10]. However, a recent literature review and meta-analysis
concluded that the impact of chemotherapy-related toxicity
on the patients’ quality of life has been insufﬁciently
studied in patients with advanced gastric cancer [7].
Webb et al. compared the combination of epirubicin,
cisplatin and 5-FU (ECF) with 5-FU, doxorubicin and
methotrexate (FAMTX) in previously untreated patients
with advanced esophagogastric cancer [11]. Using the
EORTC QLQ-C30, the authors showed that ECF resulted
in a better QL at 24 weeks compared with FAMTX. Sub-
sequently, Ross et al. (2002) showed that ECF resulted in a
better QL at 3 and 6 months when compared with myto-
mycin C, cisplatin and 5-FU (MCF) [12]. ECF has never
been directly compared with CF, although a meta-analysis
suggests ECF has a survival advantage over CF. However,
concerns remain over the toxicity of ECF and the role of
epirubicin in the combination [13]. More recently, Van
Cutsem et al. (2006) compared the combination treatments
docetaxel plus cisplatin and ﬂuorouracil (DCF) vs. cisplatin
and ﬂuorouracil (CF) as ﬁrst-line therapy for advanced
gastric cancer [14]. The study met its primary endpoint
showing a signiﬁcant improvement in time-to-progression
(TTP) with DCF compared with CF, and also an
improvement in survival, and response rate were reported.
Although, higher incidences of toxicity were observed in
the DCF treatment arm, this did not appear to impact on
QL which was signiﬁcantly better in the DCF arm. These
results suggest that better tumour control may also have
lead to better symptom control in the DCF arm [14, 15].
Following promising results using irinotecan in combi-
nation with either 5-FU or cisplatin in phase II trials [16–
19], a phase II–III trial was initiated in previously untreated
advanced gastric adenocarcinoma patients comparing iri-
notecan plus cisplatin with irinotecan plus 5-FU given as
an infusional AIO regimen (IF) [20]. Based on the risk/
beneﬁt ratio for IF in this study, a phase III trial was
designed to compare IF to cisplatin plus 5-FU administered
using a 5-day infusional regimen (CF). QL results for the
phase III part of the study are reported here. The clinical
results and initial QL results have been presented else-
where [21].
As with other studies [14], the initial analysis of the QL
data for the current study was carried out using time-to-
event analysis (e.g. time to a 5% deterioration of the global
health status/QL scale) in accordance with the statistical
analysis plan. It is generally considered that for QL data,
time-to-event analysis is limited since it does not take into
account the repeated measures aspect of the data or the
potential bias introduced by missing data. The analysis
presented in this report addresses the fact that QL is a
process and consequently is subject to change over time,
that measurements taken at different time points are cor-
related, and that patients drop out during the study or have
intermittent missing data, thus taking the entire structure of
the QL data into account.
Patients and methods
Patient eligibility
Patients were to have histologically conﬁrmed adenocar-
cinoma (including diffuse type, intestinal type and linitis)
of the stomach or esophagogastric junction, with measur-
able or evaluable metastatic disease (cytology or histology
was mandatory if a single metastatic lesion was the only
manifestation of disease) or locally recurrent disease with
at least one measurable lymph node. Patients were also
required to be between 18 and 75 years of age, have Kar-
nofsky performance status (KPS) [70%, life expectancy
[3 months and adequate haematological parameters. The
study was conducted in accordance with the Declaration of
Helsinki and was approved by national or local ethics
committees, as appropriate. All patients provided written
informed consent. Further details regarding patient eligi-
bility are provided elsewhere [21].
Study treatments
Subjects randomised to the IF arm were scheduled to
receive irinotecan 80 mg/m
2 over a 30-min i.v. infusion,
followed by FA 500 mg/m
2 as a 2-h i.v. infusion, imme-
diately followed by 5-FU 2,000 mg/m
2 over a 22-h i.v.
infusion, day 1 every week for 6 weeks followed by a
1-week rest. In the CF arm patients were scheduled to
receive cisplatin 100 mg/m
2 as a 1–3-h i.v. infusion, day 1,
followed by 5-FU 1,000 mg/m
2/day over a 24-h i.v.
infusion, days 1–5, and every 4 weeks. Treatment was
administrated until disease progression, unacceptable
toxicity or withdrawal of consent.
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123Study design
The primary objective of the phase III part of the study was
to detect a statistically signiﬁcant increase in TTP for the
IF arm relative to the CF arm. In addition, a non-inferiority
comparison was speciﬁed in the protocol, in case of a non-
signiﬁcant trend towards superiority of TTP for the IF arm
[22, 23]. Tumour progression was assessed according to
World Health Organization Criteria and TTP measured
from randomisation until the date of progression or death.
Randomisation was performed using the minimisation
technique [24], stratifying patients according to presence of
measurable vs. evaluable disease, liver involvement,
baseline weight loss, prior surgery and centre.
QL assessments
TheEORTCQLQ-C30(version3.0)andEuroQoL(EQ-5D)
instruments were used in this study. The QLQ-C30 is a
cancer speciﬁc, self administered assessment of QL. The
scale scores were calculated as per the scoring procedure
deﬁned in the EORTC QLQ-C30 Scoring Manual [25]. The
EQ-5D is also a self-administered instrument comprising
ﬁvequestionsandavisualanaloguescale,whichrepresentsa
rating of the patient’s health state [26]. The ﬁve single items
are combined to obtain a health utility index (HUI) score.
This report focuses on the global health status\QL, physical
functioning, social functioning, pain and nausea/vomiting
scales of the EORTC QLQ-C30 and the two EQ-5D scales.
Quality of life assessments were required at baseline,
every 8 weeks until documentation of disease progression
and every 3 months from the documentation of the pro-
gression until death. To be considered evaluable at base-
line, a questionnaire must have been ﬁlled in within
15 days before randomisation. To be considered evaluable
on treatment, a questionnaire had to be ﬁlled in more than
5 days (IF arm) or 9 days (CF arm) after the start of the
latest infusion so as not to take into account the immediate
toxicities following infusion. The different lag durations
after the start of the infusion allowed for the different
infusion durations to be taken into account (1 day in the IF
arm, 5 days in the CF arm).
Questionnaires without a date of assessment, or ﬁlled in
after the cut-off date or after a further anti-tumour therapy
were excluded (i.e. considered non-evaluable). Since
assessments were planned to be evaluated independently
from cycle duration, data were to be analysed according to
time windows (8 week periods, i.e. ±4 weeks of the the-
oretical assessment date for assessments before investigator
documented progressive disease). In case of multiple
evaluable questionnaires in a time window, the mean value
per subject for each scale in the time window was
calculated.
Questionnaires excluded from the analysis were either
considered present but not evaluable (i.e. see above
description) or missing. The reason for missing question-
naires was collected on the CRF pages. The reasons were
categorised as follows: random (i.e. administrative and
similar reasons not directly related to patient QL), QL
related (e.g. the patient was too ill to complete the ques-
tionnaire) or dead.
Statistical methods
Quality of life compliance was calculated as the ratio of the
total number of subjects with at least one evaluable ques-
tionnaire per time window over the total number of
expected questionnaires [27]. Patients were counted in the
total number of expected questionnaires in the window
only until further anti-tumour therapy or death prevented
assessment.
Summary measures of QL scores were generated: i.e.
the minimum, maximum and mean post-baseline QL scores
within each patient, for each scale over all evaluable
questionnaires, were calculated and summarised by treat-
ment group. The Wilcoxon non-parametric test was used to
compare treatment groups as the summary measures, par-
ticularly for the minimum and maximum, were not
expected to be normally distributed.
A logistic regression model was ﬁtted to test if the QL
data missing from patients who dropped out was missing
completely at random (MCAR) [28]. The model included
terms for time (as a linear variable expressing the 8-weekly
assessment time points), treatment (as a binary variable),
time by treatment interaction and two terms representing
global health status\QL scores: (1) sum of the two previous
scores and (2) the difference between the two previous
scores. The P-value for the Wald chi-squared statistic was
used to test the effect of QL scores on dropout.
A pattern-mixture model was ﬁtted in SAS using Proc
Mixed [29, 30]. This model allows one to model the
repeated measures structure of the data taking into account
the dropout pattern. Terms in the model included treatment,
time, dropout pattern and their interactions. Thus, a priori,
the ﬁxed effects as well as the covariance parameters were
allowed to vary unconstrained according to the dropout
pattern. In addition, several baseline clinical variables (age,
gender, WHO performance status, pain assessed by the
clinician, prior surgery and weight loss) were considered as
covariates in the model. Model reduction was carried out
using a likelihood ratio test to identify the most parsimo-
nious model consistent with the data. If the treatment effect
in the ﬁnal model was pattern dependent, the delta method
would be used to obtain the marginal treatment effect [31].
As such, the treatment effect is estimated within each
pattern and the overall marginal treatment effect is
Qual Life Res (2009) 18:853–861 855
123estimated using a weighted summation of the individual
within pattern treatment effects, weighted according to the
proportion of subjects in each dropout pattern. The null
hypothesis of no treatment effect would be tested using a
Wald statistic, which approximates a chi-squared distri-
bution with one degree of freedom.
Results
Clinical results
Between June 2000 and March 2002, 337 patients were
randomised (172 IF, 165 CF). Two patients in each arm
were never treated, one due to disease progression and
three due to adverse events. Thus the full analysis popu-
lation, deﬁned as treated patients analysed in the arm to
which they were randomised, consisted of 333 patients
(170 IF, 163 CF). The median treatment duration was 21
and 17 weeks in the IF and CF arms, respectively. The
proportion of patients for whom an adverse event was
reported as the reason for discontinuation was higher in the
CF arm (10.0% IF, 21.5% CF; P = 0.004). A non-signiﬁ-
cant trend towards a longer median time-to-progression
(TTP) was observed in the IF arm (5.0 months) compared
with the CF arm (4.2 months: P = 0.088). The non-infe-
riority criteria, that the lower limit of the 95% CI of the
Cox hazard ratio be at least 0.93, was satisﬁed for TTP in
the full analysis population but not in the per protocol
population. The median overall survival was 9.0 and
8.7 months in the IF and CF arms, respectively.
Safety was assessed in the 333 treated patients,
according to treatment actually received (167 patients IF,
166 patients CF). A total of six treatment-related deaths
occurred, one in the IF arm and ﬁve in the CF arm. The rate
of hospitalisations was similar between arms, including the
rate of hospitalisations due to toxicity (27.6% of patients).
Neutropenia grade 3–4 was observed in 24.8 and 51.6% of
IF and CF patients, respectively. Thrombocytopenia grade
3–4 was observed in 1.8 and 11.7% of IF and CF patients,
respectively. Diarrhoea was observed more frequently in
the IF arm (21.6 vs. 7.2% grade 3–4) whereas stomatitis
was more prevalent in the CF arm (16.9 vs. 2.4%). Neu-
rological toxicity was also more frequent in the CF arm,
with 22.9% of patients experiencing grade 1–4 events,
compared with 5.4% in the IF arm. Further clinical results
are provided elsewhere [21].
QL compliance
Table 1 presents the compliance of the EORTC QLQ-C30
questionnaires by treatment group. The number of patients
in each time window decreased over time due to attrition of
patients. The compliance rate was higher in the IF arm at
weeks 8, 16, 24, 40 and 48. The overall compliance rates
were 60 and 56% in the IF and CF arms, respectively.
Sixteen patients did not complete any evaluable question-
naires during this period. Monotone dropout patterns (i.e. a
complete series of questionnaires before dropout) were
observed in 202 cases. The remaining 115 patients had
intermittent missing questionnaires. Of the 202 monotone
dropout cases, 98 patients completed the baseline ques-
tionnaire only.
Table 2 presents the reasons for missing\non-evaluable
questionnaires. During the ﬁrst 48 weeks, a total of 63 and
57 assessments which were present were excluded from the
analysis because of non-evaluability in the IF and CF
treatment arms, respectively. The main reason for missing
assessments at earlier visits (i.e. baseline, weeks 8 and 16)
was due to administrative and similar reasons not directly
related to patient QL, whereas the main reason for missing
questionnaires at later time points was due to death.
Summary measures
The minimum, maximum and mean post-baseline QL scale
scores were calculated for each patient and summarised by
treatment group (see Table 3). There was no signiﬁcant
Table 1 Analysis of compliance for QLQ-C30 questionnaires by protocol-planned assessment (full analysis population-randomisation group)
Time window
(TW)
IF (N = 170) CF (N = 163)
No. Pts
in TW (N1)
No. Pts with at least
one questionnaire (N2)
Rate: N2/N1 (%) No. Pts in TW
(N1)
No. Pts with at least
one questionnaire (N2)
Rate: N2/N1 (%)
Baseline 170 145 85.3 163 143 87.7
Week 8 162 97 59.9 149 79 53.0
Week 16 138 76 55.1 126 57 45.2
Week 24 106 55 51.9 91 35 38.5
Week 32 73 27 37.0 63 26 41.3
Week 40 44 19 43.2 29 11 37.9
Week 48 29 14 48.3 16 3 18.8
*Time windows up to 1 year
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123difference in QL scores between treatment groups for the
minimum global health status\QL scale. However, there
was a non-signiﬁcant trend towards a difference when
comparing the maximum (P = 0.062) and mean global
health status\QL scores (P = 0.061) between groups sug-
gesting a trend towards a better QL for patients receiving
IF. The physical functioning scale and the EQ-5D ther-
mometer consistently presented signiﬁcantly better results
for all summary measures in favour of the IF treatment
arm. The nausea\vomiting scale and EQ-5D HUI also
indicated signiﬁcant results for both the minimum and
mean summary measures in favour of the IF treatment arm.
Trends in favour of IF were also exhibited for the social
functioning and pain scales.
Testing the dropout process
Table 4 presents the logistic regression analysis of dropout.
The two QL terms in the model ‘‘difference in QL’’ and
‘‘sum of QL’’ were signiﬁcant indicating that if the sum of
the two previous QL scores were low then the probability
of dropout was high and if there was a decrease in QL score
from the previous assessment then the probability of
dropout was also high. Thus, the missing data are not
MCAR and caution needs to be taken when analysing the
QL data.
Figure 1 presents the mean global health status\QL
scores by time and dropout pattern for each treatment
group. Dropout patterns were deﬁned based on the time of
the last completed questionnaire. Four patterns were
deﬁned as follows: 1 = dropout at baseline, 2 = dropout at
week 8 or 16, 3 = dropout at week 24 or 32, 4 = dropout
after week 32. This resulted in 80, 88, 91 and 58 patients in
the four patterns, respectively, with sufﬁcient data within
each pattern to carry out formal statistical analyses. Fig-
ure 1 illustrates that the mean global health status\QL score
increased initially in all patterns in the IF treatment arm,
however the mean scores subsequently decreased prior to
dropout indicating that there was an initial improvement in
global health status\QL score, possibly due to treatment,
and a subsequent deterioration prior to dropout. In both
treatment groups, there is a clear indication of differences
between patterns with respect to mean global health sta-
tus\QL score. The ﬁndings from Fig. 1 are consistent with
the logistic regression analysis, in particular it illustrated
that patients with a low QL score and a decrease in QL had
a higher probability of dropout.
Model ﬁtting
Several baseline clinical variables were considered as
covariates in the model. The ﬁnal model included an
autoregressive order 1 variance–covariance structure, the
baseline variables pain and WHO performance status and
the treatment by pattern interaction and the main time
effect. As there was an interaction between the treatment
effect and pattern the treatment effect was estimated using
the delta method. Figure 2 presents the treatment estimates
for all the QL variables investigated except for the EQ5D
HUI score (P = 0.518) which is on a different scale. Sig-
niﬁcant treatment differences were observed for the phys-
ical functioning scale, nausea\vomiting and EQ-5D
thermometer in favour of the IF treatment arm. All the
other scales illustrated non-signiﬁcant results.
Table 2 Reasons for missing\non evaluable questionnaires
Time window
(TW)
Treatment Missing\non-
evaluable
questionnaire
Reason
Present but non-
evaluable
Random QoL related Dead Unknown
Baseline IF (N = 170) 25 (14.7) 13 (7.7) 7 (4.1) 0 (0.0) 0 (0.0) 5 (2.9)
CF (N = 163) 20 (12.3) 7 (4.3) 12 (7.4) 0 (0.0) 0 (0.0) 1 (0.6)
Week 8 IF (N = 170) 73 (42.9) 5 (2.9) 39 (22.9) 13 (7.7) 8 (4.7) 8 (4.7)
CF (N = 163) 84 (51.5) 6 (3.7) 52 (31.9) 8 (4.9) 7 (4.3) 11 (6.8)
Week 16 IF (N = 170) 94 (55.3) 13 (7.7) 44 (25.9) 9 (5.3) 17 (10.0) 11 (6.5)
CF (N = 163) 106 (65.0) 9 (5.5) 49 (30.1) 13 (8.0) 23 (14.1) 12 (7.4)
Week 24 IF (N = 170) 115 (67.7) 8 (4.7) 39 (22.9) 7 (4.1) 41 (24.1) 20 (11.8)
CF (N = 163) 128 (78.5) 13 (8.0) 37 (22.7) 8 (4.9) 52 (31.9) 18 (11.0)
Week 32 IF (N = 170) 143 (84.1) 13 (7.7) 30 (17.7) 12 (7.1) 73 (42.9) 15 (8.8)
CF (N = 163) 137 (84.1) 10 (6.1) 29 (17.8) 9 (5.5) 75 (46.0) 14 (8.6)
Week 40 IF (N = 170) 151 (88.8) 8 (4.7) 28 (16.5) 4 (2.4) 98 (57.7) 13 (7.7)
CF (N = 163) 152 (93.3) 9 (5.5) 31 (19.0) 7 (4.3) 99 (60.7) 6 (3.7)
Week 48 IF (N = 170) 156 (91.8) 3 (1.8) 26 (15.3) 2 (1.2) 116 (68.2) 9 (5.3)
CF (N = 163) 160 (98.2) 3 (1.8) 40 (24.5) 3 (1.8) 110 (67.5) 4 (2.5)
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In this study, preliminary analysis using summary mea-
sures was carried out in an exploratory fashion. There were
a number of signiﬁcant results in the comparison of the two
treatment groups consistently indicating a better QL in the
IF treatment group. The main differences between treat-
ment groups were observed for the physical functioning
and nausea\vomiting scales from the EORTC QLQ-C30
and the two EQ-5D scales. Non-signiﬁcant trends towards
a difference were observed for the social functioning, pain
and global health status\QL scale in favour of IF.
More questionnaires were completed in the IF arm than
in the CF arm. As such the probability of observing an
extreme result (e.g. minimum or maximum) is increased in
the IF arm since the more frequently a process is observed
the more often one will observe an extreme result. The
number of questionnaires and the patterns of completion of
questionnaires also varied considerably between patients.
Missing data were prevalent. It was shown that missing data
at earlier time points were due mainly to random reasons,
e.g. administrative failure whereas missing questionnaires
at later time points were missing mainly due to death. As
Table 3 Summary measures for secondary QL endpoints
Scale Statistic Summary measure IF CF P-value
aGlobal health status\QL N 116 101
Mean (SD) Minimum 55.06 (21.90) 51.24 (21.19) 0.259
Maximum 68.75 (21.92) 62.38 (24.05) 0.062
Mean 62.41 (20.05) 56.95 (21.10) 0.061
aPhysical functioning N 117 101
Mean (SD) Minimum 72.19 (23.47) 66.01 (24.57) 0.050
Maximum 86.15 (15.98) 75.70 (23.14) \0.001
Mean 79.60 (17.68) 71.05 (22.55) 0.003
aSocial functioning N 116 102
Mean (SD) Minimum 66.45 (29.52) 62.77 (28.90) 0.329
Maximum 84.34 (20.88) 76.80 (28.04) 0.053
Mean 76.28 (22.25) 70.62 (26.72) 0.164
bPain N 117 102
Mean (SD) Minimum 13.96 (23.16) 19.44 (27.03) 0.092
Maximum 31.48 (29.40) 31.73 (30.65) 0.970
Mean 21.54 (23.24) 24.65 (26.51) 0.500
bNausea\vomiting N 116 102
Mean (SD) Minimum 7.76 (16.07) 15.06 (22.32) 0.001
Maximum 21.12 (22.56) 27.12 (27.40) 0.150
Mean 13.62 (16.80) 20.82 (23.06) 0.026
aEQ-5D thermometer N 87 69
Mean (SD) Minimum 67.98 (19.18) 58.32 (18.68) 0.003
Maximum 78.91 (16.10) 70.76 (19.08) 0.002
Mean 73.66 (16.56) 64.80 (17.49) 0.002
aEQ-5D HUI N 86 66
Mean (SD) Minimum 0.69 (0.29) 0.58 (0.29) 0.003
Maximum 0.82 (0.21) 0.73 (0.29) 0.110
Mean 0.76 (0.23) 0.66 (0.27) 0.018
a A higher score represents a higher level of functioning and a better QL
b A higher score represents a higher level of symptom
Table 4 Logistic regression of dropout
Parameter Estimate Standard
error
Chi-squared P-value
Intercept 0.0146 1.0063 0.0002 0.9884
Time -0.2350 0.2544 0.8535 0.3556
Treatment -0.0857 0.3681 0.0542 0.8159
Time 9 treatment 0.1599 0.1097 2.1245 0.1450
Difference in QL -0.0182 0.0064 8.2306 0.0041
Sum of QL -0.0079 0.0029 7.1555 0.0075
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123such it may be argued that intermittent missing question-
naires were primarily due to random reasons (i.e. MCAR),
whereas monotone missingness were due to progression of
disease or death. This latter point is supported by testing the
dropout process. Testing the dropout process indicated that
questionnaires at the time of dropout were not MCAR. The
results indicated that if QL scores were low then the prob-
ability of dropout was high. This phenomenon was con-
ﬁrmed when plotting the mean global health status\QL
scores over time by dropout pattern. The imbalance in
compliance and the dropout of patients suggests that sim-
pliﬁed analyses such as time-to-event analysis and analysis
using summary measures may be biased. Consequently,
more complex analyses were carried out using pattern-
mixture models to reduce any potential bias.
The ﬁnal pattern-mixture model indicated that mean QL
scores were dependent on dropout pattern and that the
variance–covariance structure had an autoregressive
component. Analysing the data neglecting to take this
information into account could be considered wasteful and
potentially biased. Using the pattern-mixture model, sig-
niﬁcant treatment differences were observed for the physi-
cal functioning scale, nausea\vomiting and EQ-5D
thermometer in favour of the IF treatment arm. These
results were mainly consistent with those using the mean as
a summary measure. However, for most scales the treatment
effect was less signiﬁcant using the pattern-mixture model.
This is partially explained by the fact that between patient
variation is artiﬁcially reduced using summary measures
thus resulting in larger effect sizes. The ﬁndings of the QL
analysis are also consistent with the toxicity proﬁle as
recorded through adverse event reporting [21]. While the
rates of diarrhoea, cholinergic syndrome and fever without
infection were higher in patients receiving IF, these symp-
toms were manageable in the current study. The higher rates
of neurological toxicities, anorexia, stomatitis, alopecia,
febrile neutropenia/neutropenic infection, thrombocytope-
nia and creatinine elevation in the CF arm, in addition to
nausea and vomiting, are consistent with a negative impact
on the physical functioning and nausea\vomiting scales.
This was also reﬂected in the signiﬁcantly higher number of
withdrawals due to treatment-related AEs in the CF arm. In
addition, the previously reported advantages in terms of
efﬁcacy (TTP and time to treatment failure) and clinical
beneﬁt (KPS, appetite and weight loss) all favoured patients
receiving IF [21].
Analysis of the QL data using pattern-mixture analysis
yielded more signiﬁcant results than using time-to-event
analysis. The original analysis of this study and other
studies have used time-to-event analyses [14, 21]. However
analyses of QL data using time-to-event are limited and
potentially biased for a number of reasons. For example,
when analysing the global health status\QL scale, 58% of
patients had censored time-to-events. In analysis of QL
data of advanced gastric patients where the time-to-event is
time-to-deterioration of QL one could argue that there is
informative censoring, i.e. missing questionnaires after
dropout are not MCAR and consequently the probability of
Fig. 1 Plot of the least squares means estimates of the EORTC QLQ-
C30 mean global health status by treatment group and dropout
pattern. A higher score represents a better QL. Full green line
represents pattern 4 (i.e. dropout after week 32). Other lines represent
patterns 1–3, i.e. dropout at baseline, dropout at week 8 or 16, dropout
at week 24 or 32, respectively
Fig. 2 Testing the treatment
effect using the delta method.
EQ-5D HUI is on a different
scale and consequently is not
included in this ﬁgure
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123being censored is not completely at random. This is par-
ticularly important in this study when analysing the global
health status\QL scale as the majority of patients had
censored time-to-events. Conversely, only 42% of patients
had observed the event of interest (i.e. deterioration of QL
score). As the number of QL events is small the power to
detect a treatment difference is small. Consequently, even
if large differences are expected between treatment groups,
the probability of observing a signiﬁcant difference is
small. Thus time-to-event analyses would appear to be
potentially biased and wasteful for analysing QL data.
Currently, there is no internationally agreed upon gold
standard for conducting and reporting QL studies in cancer
clinical trials [32]. While other authors have also used the
EORTC QLQ-C30 questionnaire in advanced gastric can-
cer, sometimes reporting of results was poor and was
limited to a few paragraphs within the overall clinical
paper [11, 12, 14]. For example, details concerning com-
pliance within treatment arms were not provided and
methods of analysis were sub-optimal as they did not take
into account the structure of the data, i.e. repeated (corre-
lated) measurements with missing data. It is imperative that
sufﬁcient details concerning QL assessment, analysis and
reporting are provided to allow comparisons of ﬁndings
across studies. This is particularly relevant in diseases such
as advanced gastric cancer where survival rates are similar
across treatment regimens.
The use of irinotecan-based regimens for the treatment
of advanced gastric cancer has been further explored in
phase II studies during the last few years, especially with
the availability of new targeted agents [33–35]. Although
initial results are promising, suggesting that IF could rep-
resent a potential platinum-free alternative backbone to be
combined with new targeted agents, results from phase III
studies are required before drawing any ﬁrm conclusions.
QoL assessment should be incorporated as a prominent
objective in phase III studies in advanced gastric cancer to
help both patients and physicians to discuss treatment
choices and aid decision making [6, 7].
In summary, there was a trend in favour of IF over CF in
time-to-progression. The IF treatment arm also demon-
stratedabettersafetyproﬁlethantheCFarmandabetterQL
on a number of multi-item scales. These results would sug-
gest that IF offers an alternative platinum-free ﬁrst-line
treatment option for advanced gastric cancer which should
beexploredfurtherincombinationwithnewtargetedagents.
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